In the last month, there has been a flurry of activity at the PTAB related to challenges from biosimilar manufacturers related to ustekinumab, aflibercept, and eculizumab patents…. By: Goodwin
Previous Story
ESO Solutions Data Breach Update: ESO Solutions Announces Data Breach
